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Abstract: Pheochromocytoma/paragangliomas (Pheo/PGL) are rare endocrine cancers with strong genetic 
background. Mutations in the SDHB subunit of succinate dehydrogenase (SDH) predispose patients to 
malignant disease with limited therapeutic options and poor prognosis. Using a host of cellular and 
molecular biology techniques in 2D and 3D cell culture formats we show that SDH inhibition had cell line 
specific biological and biochemical consequences. Based on our studies performed on PC12 (rat chromaffin 
cell line), Hela (human cervix epithelial cell line), and H295R (human adrenocortical cell line) cells, we 
demonstrated that chromaffin cells were not affected negatively by the inhibition of SDH either by siRNA 
directed against SDHB or treatment with SDH inhibitors (itaconate and atpenin A5). Cell viability and 
intracellular metabolite measurements pointed to the cell line specific consequences of SDH impairment 
and to the importance of glutamate metabolism in chromaffin cells. A significant increase in glutaminase-
1 (GLS-1) expression after SDH impairment was observed in PC12 cells. GLS-1 inhibitor BPTES was 
capable of significantly decreasing proliferation of SDH impaired PC12 cells. Glutaminase-1 and SDHB 
expressions were tested in 35 Pheo/PGL tumor tissues. Expression of GLS1 was higher in the SDHB low 
expressed group compared to SDHB high expressed tumors. Our data suggest that the SDH-associated 
malignant potential of Pheo/PGL is strongly dependent on GLS-1 expression and glutaminases may be 
novel targets for therapy. 
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1. Introduction 
The unique metabolic environment of cancers is long known [1]. Pheochromocytomas/paragangliomas 
(Pheo/PGL) are rare (incidence: 0.8 per 100,000 person-years [2]) chromaffin cell derived neoplasms. In the 
past decade, enzymes of the tricarboxylic acid (TCA) cycle became the center of attention, because variants 
of genes encoding the subunits of succinate dehydrogenase enzyme [3–6], fumarate hydratase [7], malate 
dehydrogenase type 2 [8], and aspartate aminotransferase [9] enzymes have been associated with 
development of Pheo/PGL. The most widely accepted assumption is that defects of tricarboxylic acid (TCA) 
cycle may result in accumulation of certain, so called oncometabolites (such as succinate, fumarate, D-2-
hydroxyglutarate [10]) which contribute to cancer development. Succinate competitively inhibits the 2-
oxoglutarate (2-OG)-dependent HIF prolyl-hydroxylases in the cytosol [11,12], which results in stabilization 
and activation of HIF-1α therefore a shift to a pseudo-hypoxic environment occurs. This phenomenon is 
further demonstrated by the highly vascular phenotype of these tumors. In addition, chronic hypoxia (i.e., 
high altitudes) increases the incidence of sporadic PGLs and it has been demonstrated that it has a 
phenotype modifier effect on germline SDHB and SDHD mutant PGLs [13–16]. 
Even though germline mutations of genes encoding for SDH subunits have been shown to predispose 
susceptibility for the development of familial Pheo/PGL, only mutations of the SDHB gene have been often 
associated with high rate of malignancy. Metastatic disease can be observed in more than 17–40% of patients 
with SDHB mutations [17–19], but the mechanisms leading to the malignant phenotype are still unclear. 
The lack of a useful in vivo animal model for the development of Pheo/PGLs highly determines the 
experimental opportunities. [20]. Due to the lack of response to the currently available therapy for malignant 
Pheo/PGL, novel and easily accessible in vitro models for this tumor are required in order to evaluate the 
candidate therapies and to uncover new prognostic and therapeutic targets. 
Glutamine is a major source of carbon for nucleotide and non-essential amino acid biosynthesis [21], 
and its metabolism supports cell proliferation [22]. Glutamine also serves as an energy source through 
glutamine-driven oxidative phosphorylation [23], as it replenishes TCA intermediates. SDHB-deficient cells 
show increased glutamine incorporation, which might be used as a shuttle for aspartate from the 
mitochondria to the cytosol to support cellular anabolism [24]. Glutamine metabolism also yields precursors 
for glutathione production, thus plays an important role in maintaining the redox homeostasis of cancer 
cells [25–27]. Furthermore, glutaminolysis supports substrate-level phosphorylation during hypoxia in 
tumors [28]. 
Located in the mitochondria, glutaminase-1 (GLS-1) generates glutamate from glutamine. Glutamate 
can be further metabolized to α-ketoglutarate, by glutamate dehydrogenase (GDH), which can directly fuel 
the TCA cycle. GLS-1 has been found to be upregulated in some cancers, and in some cases deregulated 
glutamine metabolism is essential for cancer growth [29–32]. SDHx mutant tumors were shown to 
accumulate lower levels of glutamate [33], and SDHB knockout cells were shown to be more sensitive to 
GLS-1 inhibitors [34]. Targeting glutamine metabolism in SDH deficient cancer is emerging as an ongoing 
trial (NCT02071862) including, inter alia, SDH associated gastrointestinal stromal tumors and non-
gastrointestinal stromal tumors. However, to date, there are only very limited published data available 
about the efficacy of GLS-1 inhibitors in SDHB related malignancies [35]. 
Itaconate is a natural metabolite, in vivo it is synthesized in macrophages from cis-aconitate by cis-
aconitase, coded by Irg1 (immunoresponsive gene 1) in order to dysregulate bacterial metabolism [36]. 
Itaconate contributes to macrophages’ antimicrobial activity by inhibiting isocitrate lyase of bacteria [37,38] 
and to limit neuronal Zika virus infection by inducing an antiviral intracellular metabolic state [39]. 
Itaconate can reduce the activity of SDH in vitro [40] in a dose dependent manner, but has no effect on other 
mitochondrial pathways [41]. 
In addition, it was shown that itaconate can facilitate tumor progression through a ROS-driven 
pathway [42]. It was demonstrated that peritoneal tissue-resident macrophages promote tumor progression 
in certain tumors, including melanoma and ovarian carcinoma by tumor induced Irg1 expression resulting 
in high itaconic acid levels. This pro-tumor effect was associated with the reactive oxygen species mediated 
Cancers 2020, 12, 599 3 of 26 
 
MAPK activation in tumor cells [43], to the best of our knowledge, there are no data examining the effects 
of itaconate on cell survival. 
Atpenin A5 (atpenin) is an SDH inhibitor that binds in the ubiquinone binding pocket comprised of 
residues from SDH subunits B, C, and D, blocking the electron transfer between the enzyme and ubiquinone 
[44,45]. It is important to note that the inhibition of SDH with atpenin could not induce hypoxia mediated 
gene expression in monocytes [46] and a dose dependent reduction of cell survival after treatment with 
atpenin analogues has been shown [47]. 
In this current work we aimed to study the biological and metabolic consequences of accumulation of 
succinate obtained through pharmacological and translational inhibition of the SDH enzyme in various 
cancer cell lines and using siRNA knockdown of Sdhb in rat pheochromocytoma cell line, PC12. Our 
complex in vitro study revealed that SDH inhibition facilitated the viability of chromaffin cells but not the 
non-chromaffin cells. Selective inhibition of GLS-1 enzyme decreased the proliferation of SDH impaired 
PC12 cells in monolayer and in 3D tissue culturing. Based on our in vitro findings, we detected an 
upregulation of GLS-1 in SDHB-low expressed Pheo/PGL tumors compared to SDHB highly expressed 
Pheo/PGLs. Our data pointed to the importance of the choice of cell line for studying SDH impairment and 
indicated the potential prognostic role and therapeutic target of GLS-1 enzyme in SDH-associated 
malignant Pheo/PGL. 
2. Results 
2.1. Sdhb Targeting siRNA Effectively Decreased SDH Activity 
PC12 cells were transfected with two different Sdhb targeting siRNAs. After 48 h incubation, SDH 
activity SDHB protein levels and succinate/fumarate ratios were assessed. SDH activity was effectively 
reduced after siSdhb transfection compared to mock transfected and untreated cells (Figure 1A–D). siSdhb 
transfection showed similar potential in inhibiting SDH activity to atpenin, a potent and known SDH 
inhibitor (Figure 1D). Combination of two SDHB targeting siRNAs effectively reduced SDHB protein levels 
(Figure 1E,F and Figure S1). Succinate/fumarate ratio increased significantly in cells transfected with siRNA 
against Sdhb compared to cells transfected with mock siRNA (p < 0.0001) (Figure 1G). 
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Figure 1. Effects of Sdhb knockdown in PC12 cells. (A–C) Oxygen consumption PC12 cells. Grey trace 
represents the negative time derivative of oxygen concentration, divided by mitochondrial mass per volume. 
Additions of substances are indicated by arrows. ADP: 0.2 mM. cATR: 2 µM. SF 6847: 1 µM. (A) Respiration 
of siSdhb transfected PC12 cells. (B) Respiration of mock transfected PC12 cells. (C) Respiration of untreated 
PC12 cells. (D) Succinate dehydrogenase (SDH) activity after siSdhb transfection, mock siRNA transfection, 
atpenin treatment and in untreated PC12 cells. The effectiveness of siSdhb transfection was compared to 
atpenin, which is a well-known potent SDH inhibitor. (E) SDHB protein level after siRNA transfection using 
Western blot analysis. (F) Densitometry quantification of the SDHB protein in siRNA against Sdhb treated 
and mock siRNA transfected PC12 cells. (G) Succinate to fumarate ratio in PC12 cells transfected with SDHB 
targeting siRNA (siSdhb) compared to mock transfected cells. suc/fum: succinate to fumarate ratio. ****: p < 
0.0001. 
2.2. Itaconic Acid Treatment Successfully Inhibited SDH Activity in All Cell Lines Studied 
Succinate/fumarate ratio significantly increased in PC12 cells after 24 h (p < 0.0001) and 48 h (p < 0.0001) 
itaconate treatment. (Figure S2A) 
Similar to PC12 cells, significant increase in succinate/fumarate ratio was observed in HeLa cells after 
24 h (p < 0.0001) and 48 h (p < 0.0001) itaconate treatment, as well as in H295R cells after 24 h (p < 0.0001) 
and 48h (p < 0.0001) itaconate treatment. (Figure S2B,C) 
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2.3. Atpenin Treatment Successfully Inhibited SDH Activity in All Cell Lines Studied 
Succinate/fumarate ratios due to the immeasurable concentrations of fumarate in case of atpenin 
treatment could not be calculated. However, SDH activity was also successfully inhibited by atpenin 
treatment based on the significant (p < 0.0001) increase in succinate concentrations and the significant (p < 
0.0001) fold increase in succinate levels in all cell lines, compared to control (Figure S3). 
2.4. Cell Viability and Proliferation 
2.4.1. SDH Impairment Had an Overall Positive Effect on Cell Viability Without Significant Changes in the 
Proliferation in PC12 Cells 
Sdhb knockdown significantly increased PC12 cells’ viability after 72 h (p = 0.04) compared to mock 
transfected cells whereas significant differences were not observed at 24 and 48 h. (Figure 2A). A significant 
difference was observed in itaconic acid treated PC12 cells compared to vehicle treated cells after 24 h (p = 
0.026) but not at 48 and 72 h (Figure 2B). Atpenin treatment yielded an increase in cell viability, but not at a 
significant level in the PC12 cell line (Figure 2C). 
Cell proliferation of PC12 cells measured with SRB assay was not affected by SDH impairment either 
with Sdhb knockdown or itaconate/atpenin treatment (Figure 2D–F). 
 
Figure 2. Cell viability and proliferation of PC12 cell lines. Data is presented in mean ± SEM. Cell viability 
measurement values are normalized to the control values. A total of 100% was subtracted from the values, 
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therefore, changes in % compared to control are presented. (A–C) Relative change of cell viability of Sdhb 
targeting siRNA transfected, itaconate, or atpenin treated PC12 cells after 24, 48, and 72 h incubation, 
compared to control. (D–F) Proliferation of PC12 cells after Sdhb targeting siRNA transfection, itaconate, or 
atpenin treatment measured by SRB assay. Ita: Itaconate; veh: vehicle. SRB: Sulforhodamine B; *: p < 0.05. 
2.4.2. Itaconate Decreased Cell Viability of HeLa and H295R Cells Whereas Atpenin Only Decreased Cell 
Viability in the H295R Cell Line 
HeLa cells showed significant decrease in cell viability upon 48 h (p = 0.002) and 72 h (p = 0.002) 
treatment with itaconate. The opposite effect was observed after atpenin treatment of HeLa cells with 
significant increase in cell viability at 48 h (p = 0.015) compared to vehicle treatment (Figure 3A,B). 
The H295R cell line showed an overall negative response to SDH impairment: significant decrease in 
cell viability was observed upon itaconate treatment after 72 h (p = 0.0043) and upon atpenin treatment after 
24 h (p = 0.004) and 48 h (p = 0.017) (Figure 3C, D). 
 
Figure 3. Cell viability measurements of HeLa and H295R cell lines. Values are normalized to the control 
values. A total of 100% was subtracted from the values, therefore, changes in % are presented compared to 
control. (A) Relative change of cell viability of HeLa cells after 24, 48, and 72 h itaconate treatment, compared 
to control. (B) Relative change of cell viability of HeLa cells after 24, 48, and 72 h atpenin treatment, compared 
to control. (C) Relative change of cell viability of H295R cells after 24, 48, and 72 h itaconate treatment, 
compared to control. (D) Relative change of cell viability of H295R cells after 24, 48, and 72 h atpenin 
treatment, compared to control. Veh: vehicle. *: p < 0.05; **: p < 0.01. 
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2.4.3. Changes in Glutamate and Lactate Concentrations were SDH Inhibition Method and Cell Line 
Specific 
The metabolite concentrations for each cell line and each SDH inhibitory method are presented in 
Figure 4 and Figure S4, and Tables S1 and S2. 
In PC12 cells metabolite concentrations measured after Sdhb knockdown clustered together to those 
measured after itaconate treatment (Figure 4B). Succinate accumulation was detected in all cell lines after 
inhibition of SDH activity. Sdhb knockdown significantly decreased glutamate concentrations (p < 0.0001) 
(Figure 4C), while lactate did not show accumulation (Figure 4D and Table S1). 
Glutamate levels also decreased in PC12 cells after itaconic acid treatment compared to vehicle 
treatment after 24 h (p = 0.008) and 48 h (p = 0.53) without lactate accumulation (Figure 4C, D and Table S1). 
Atpenin induced a significant decrease of glutamate concentrations in PC12 cells after 24 h (p < 0.0001) and 
48 h (p < 0.0001), accompanied with significant increases in lactate concentrations after 24 h (p = 0.004) and 
48 h (p < 0.0001) (Figure 4C,D and Table S2). 
Contrary to PC12 cells, glutamate (p = 0.004) and lactate (p = 0.013) concentrations significantly 
increased in HeLa cells treated with itaconic acid compared to vehicle treatment after 24 h incubation. 
Elevation of both glutamate (p < 0.0001) and lactate (p = 0.018) concentrations were also significant after 48 
h incubation (Figure S4A and Table S1). 
Atpenin treatment resulted in a significant decrease in the glutamate concentrations of HeLa cells after 
24 h (p < 0.0001) and 48 h (p < 0.0001) accompanied by significant increases in lactate concentrations after 24 
h (p = 0.0039) and 48 h (p < 0.0001) (Figure S4A and Table S2). 
In H295R cells itaconic acid treatment caused significant increase in intracellular glutamate (p = 0.018) 
and lactate (p < 0.0001) levels only after 24 h (Figure S4B and Table S1). Glutamate concentrations 
significantly decreased in H295R cells after 24 h (p < 0.0001) and 48 h (p < 0.0001) atpenin treatment 
accompanied by significant increases in lactate concentrations after 24 h (p < 0.0001) and 48 h (p = 0.004) 
(Figure S4B and Table S2). 
 
Figure 4. Inhibitory method specific changes in cellular metabolomics of PC12 cells after SDH inhibition. (A) 
Schematic illustration of Complex II. FAD: flavin-adenin-dinucleotide; FADH2: reduced FAD; Fe-S: iron-
sulfur cluster; Q: coenzyme-Q or Ubiquinone; QH2: ubiquinol; SDHA: succinate dehydrogenase subunit A; 
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SDHB: succinate dehydrogenase subunit B; SDHC: succinate dehydrogenase subunit C; SDHD: succinate 
dehydrogenase subunit D. *: the presumed inhibitory activity of itaconic acid. **: The presumed inhibitory 
activity of atpenin A5. (B) HeatMap: visualization of changes in metabolite concentrations in PC12 cell line 
after Sdhb knockdown, itaconate and atpenin treatment. Fold-changes of different metabolic concentration 
were calculated (values measured after treatment were divided with control values) then the given values 
were log2 transformed. These values were used for construction of the heatmap and represented with color 
scale (red+/white 0/green−). (C) Normalized glutamate concentrations in PC12 cells after Sdhb knockdown, 
itaconate and atpenin treatment, and vehicle treatments. (D) Normalized lactate concentrations in PC12 cells 
after Sdhb knockdown, itaconate and atpenin treatment, and vehicle treatments. atp24: 24 h atpenin 
treatment; atp48: 48 h atpenin treatment; ita24: 24 h itaconate treatment; ita48: 48 h itaconate treatment; 
siSDHB: Sdhb knockdown; SUC: succinate; LAC: lactate; PYR: pyruvate; CIT: citrate; MAL: malate; FUM: 
fumarate; GLU: glutamate; ASP: aspartate. *: p < 0.05; **: p < 0.01; ****: p < 0.0001. 
2.4.4. GLS-1 Gene Expression was Cell Line and SDH Inhibitory Method Dependent 
Based on the metabolomics and cell viability measurements we sought to assess the importance of 
glutamine/glutamate metabolism, especially the mitochondrial uptake of glutamine by glutaminase-1 (GLS-
1). A significant increase in GLS-1 expression after Sdhb knockout (fold change: 1.53 ± 0.3, p = 0.002) was 
observed in PC12 cells A significant increase in GLS-1 expression was observed after itaconate treatment of 
PC12 cells after 24 h (fold change: 1.2 ± 0.03, p = 0.015) and 48 h (fold change 1.48 ± 0.13, p = 0.002). On the 
contrary, GLS-1 expression decreased after atpenin treatment in PC12 cells after 24 h (fold change: 0.89 ± 
0.1, p = 0.065) and significant decrease was observed after 48 h (fold change: 0.82 ± 0.09, p = 0.002) (Figure 
5A). 
HeLa cells expressed a similar phenotype upon itaconate treatment: significant increase in GLS-1 
expression was observed after 24 h (fold change: 1.47 ± 0.3, p = 0.002) and 48 h (fold change: 1.9 ± 0.63, p = 
0.015) treatments. On the other hand, GLS-1 expression significantly decreased after 24 h atpenin treatment 
in HeLa cells (fold change: 0.47 ± 0.08, p = 0.002), but significantly increased after 48 h (fold change: 1.8 ± 
0.37, p = 0.002) (Figure 5B). 
H295R cells exhibited also a significant increase in GLS-1 expression after 24 h (fold change: 1.34 ± 0.1, 
p = 0.0022) and 48 h (fold change: 1.19 ± 0.1, p = 0.0152) itaconate treatment. Atpenin significantly increased 
GLS-1 expression both at 24 h (fold change: 1.78 ± 0.2, p = 0.0022) and 48 h (1.95 ± 0.2, p = 0.0022) (Figure 5C). 
 
Figure 5. Glutaminase-1 (GLS-1) expression of PC12 and HeLa cells upon SDH inhibition: all values are 
normalized to control. (A) Fold changes in GLS-1 expression in PC12 cells upon Sdhb knockdown, itaconate 
treatment, and atpenin treatment. (B) Fold changes in GLS-1 expression in HeLa cells upon itaconate and 
atpenin treatment. (C) Fold changes in GLS-1 expression in H295R cells upon itaconate and atpenin 
treatment. Ita: itaconate; i-veh: control for itaconate experiments; a-veh: control for atpenin experiments; *: p 
< 0.05; **: p < 0.01. 
2.4.5. Immunohistochemistry of SDHB and GLS-1 in Pheo/PGL Tissues Points to the Importance of GLS-1 
Enzyme 
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Based on our in vitro findings we sought to evaluate the expression level of GLS-1 in Pheo/PGLs tumor 
tissues in order to assess whether GLS-1 expression might serve as a marker for malignancy in Pheo/PGLs. 
Low (H-score < 100) SDHB staining characteristic for SDH-associated tumors was confirmed in all 
SDHB-associated tumor tissues while a high (H-score ≥ 100) staining was observed in RET-mutant tumors. 
Both high and low SDHB staining scores were observed in the sporadic tumor group (Table 1 and Figure 6). 
Increased GLS-1 expression was detected in SDHB-mutant tumor tissues compared to RET-mutant and 
sporadic tumors, however the difference was not significant (H-score: 87.8 ± 64 vs. 59 ± 82.4 SDHB-mutant 
vs. RET-mutant, p = 0.22; H-score: 87.8 ± 26 vs. 53.6 ± 47.8, SDHB-mutant versus sporadic, p = 0.15). A total 
of 54% (7 of 13) of the low SDHB expressing tumors showed high GLS-1 staining while only 22% (five of 
22) of high SDHB expressing tumors showed high GLS-1 staining (p = 0.07). 
GLS-1 was overexpressed in three RET-mutant samples. Of these three samples, in two cases 
malignancy was proved as they were reoccurring, invasive, and metastatic Pheos of Patient No. 4 (Figure 
7) and Patient No. 5. The third GLS-1 overexpressing RET-mutant Pheo sample was obtained from a patient 
with MEN2A syndrome with bilateral Pheo (Patient No. 6, the GLS-1 positive sample was the Pheo removed 
from right side). 
In the three malignant sporadic Pheo/PGL samples, two showed high SDHB staining scores. All 
malignant sporadic samples showed low or average GLS-1 immunostaining. In case of the benign sporadic 
samples, out of the four samples with low SDHB scores two were accompanied by high GLS-1 
immunostaining scores (Table 1). 
Table 1. Immunohistochemical evaluation of expression of SDHB and GLS-1 in Pheo/PGL tumor samples. 
Nr. Type of Tumor Tissue 
Biological 
Behavior Germline Mutation 
Age at Surgery 
Years 
SDHB GLS-1 
H-
Score 
H-
Score 
1 PGL Malignant 
SDHB p.C243Y 
32 0 15 
2 PGL Malignant 34 65 150 
3 PGL Malignant  SDHB p.C196G 32 10 160 
3 Pheo Malignant * SDHB p.T88I and R90 
frame shift 
14 90 110 
5 Pheo  15 70 130 
6 Pheo 
Malignant 
Benign 
RET p.C634R 
18 160 0 
7 Pheo Malignant 21 155 5 
8 Pheo Malignant 22 210 10 
9 Pheo Malignant 25 150 110 
10 Pheo Benign 
RET p.C634W 
31 123 37 
11 Pheo Malignant 34 190 160 
12 Pheo Benign (bilateral) RET p.C634R 46 200 240 
13 Pheo Benign RET p.C634Y 34 115 20 
14 Pheo Benign RET p.C609S 42 100 10 
15 Pheo Benign RET p.C634Y 63 157 7 
16 Pheo Benign sporadic 49 110 10 
17 Pheo Malignant sporadic 56 80 20 
18 Pheo Benign sporadic 47 140 120 
19 Pheo Benign sporadic 27 30 55 
20 PGL Malignant SDHB c.424-1G>A 54 0 40 
21 Pheo Benign sporadic 62 180 95 
22 PGL Malignant sporadic 82 160 10 
23 Pheo Malignant sporadic 18 120 10 
24 Pheo Benign sporadic 55 90 105 
25 Pheo Benign sporadic 56 110 10 
26 PGL Benign sporadic 30 10 135 
27 Pheo Benign sporadic 41 115 10 
28 Pheo Benign sporadic 79 110 5 
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29 Pheo Benign sporadic 53 200 105 
30 Pheo Benign sporadic 43 180 20 
31 Pheo Benign sporadic 71 - 90 
32 Pheo Benign SDHB p.Q109X 47 10 10 
33 Pheo Benign sporadic 54 190 20 
34 Pheo Benign sporadic 65 140 30 
35 Pheo Benign sporadic 59 90 115 
Tumors were considered malignant when a tumor was recurrent or local/distant metastasis were 
documented. * the patient was presented with a 16 × 13 × 9 cm Pheo, histology did not approve malignancy, 
but preoperative MRI described multiple bone metastases. n.a.: not available; Pheo: pheochromocytoma; 
PGL: paraganglioma. 
 
Figure 6. Immunohistochemistry: Immunostaining with antibodies against SDHB and GLS-1 of a 
paraganglioma associated with SDHB p. mutation (A–C) and a RET p.C634W-associated pheochromocytoma 
(D–F). Lack of SDHB staining in SDHB mutated tumors (B) and strong GLS-1 signal was detected in 
malignant SDHB-associated tumor (C). Lack of GLS-1 positive cells can be observed in RET-associated 
benign pheochromocytoma (F). Scale bar = 200 µm. H&E: hematoxylin and eosin staining. SDHB: succinate 
dehydrogenase subunit B staining. GLS-1: glutaminase-1 staining. 
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Figure 7. Immunostaining with antibodies against SDHB and GLS-1 of a RET p.C634R-associated 
pheochromocytoma. Panel A, D, G shows the hematoxylin and eosin stains of the primary tumor (A), the 
first reoccurring tumor (D) and the second reoccurring tumor (G). Strong SDHB staining (B,E,H) and lack of 
GLS-1 positive cells can be observed in a primary benign tumor (C). Slightly visible GLS-1 staining can be 
observed in the first reoccurring, invasive tumor (F) while strong GLS-1 signal was detected in the second 
reoccurring, invasive tumor (I). Scale bar = 100 µm. H&E: hematoxylin and eosin staining. SDHB: succinate 
dehydrogenase subunit B staining. GLS-1: glutaminase-1 staining. 
2.4.6. GLS-1 Inhibition in PC12 Cells Decreased Proliferation after SDH Inhibition Measured by SRB Assay 
The proliferation of PC12 cells was not significantly different upon SDH impairment, compared to 
controls (Figure 2D–F). 
To test whether SDH impaired PC12 cells’ proliferation is dependent on GLS-1 activity, we assessed 
the proliferation of the cells after BPTES treatment (BPTES is a selective GLS-1 inhibitor). Proliferation of 
PC12 cells significantly decreased when SDH inhibition was accompanied with BPTES treatment regardless 
of inhibitory methods (siRNA against Sdhb silenced cells after 72 h: p = 0.009; itaconate after 48 h: p = 0.009 
and 72 h: p = 0.009; atpenin after 48 h: p = 0.009 and 72 h p = 0.002 (Figure 8A–C). 
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Figure 8. Proliferation of SDH impaired PC12 cells upon BPTES treatment. Cell proliferation was assessed 
by SRB assay. (A–C) Effects of SDH impairment and BPTES treatment on cell proliferation of PC12 cells 
cultured in monolayer. Experiments were performed in hexuplicates. (D) The effects of itaconate and BPTES 
treatment in PC12 spheroid cell culture. The ratio of living cells to total number of cells is shown before 
treatment and after 24, 48, and 72 h incubation. All experiments were performed at least six times in each 
group. Values are shown as mean ± standard error mean. SRB: Sulforhodamine B; BPTES: bis-2-(5-
phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide; ITA: itaconate; **: p < 0.01. 
2.4.7. GLS-1 Inhibition in Itaconate Treated 3D Cultured PC12 Cells Increased the Number of Dead Cells 
Compared to Vehicle Treated Cells 
In order to assess GLS-1 inhibition in a more relevant in vitro model, we applied 3D culturing of PC12 
cells by spheroid induction using spheroid inducing media. Itaconate treatment alone did not exert a 
significant effect on the ratio of living cells (compared to vehicle treatment 3% and 9% after 48 and 72 h 
treatment, respectively). When itaconate was accompanied by BPTES treatment in the 3D cultured PC12 
cells, 18%, 13%, and 18% decreases were observed in the living cell ratios compared to vehicle treatment at 
24, 48, and 72 h, respectively (p < 0.0001 for each comparison) (Figure 8D). 
2.4.8. Oxygen Consumption Rate Measurements 
After biochemical characterization of SDH inhibition we assessed the mitochondrial respiration upon 
SDH inhibition using SeaHorse measurements in PC12 cells (Figure 9A). The effects of Sdhb knockdown 
were compared to mock transfected cells whereas the consequences of itaconate and atpenin treatment were 
compared to control (untreated) PC12 cells. 
Basal respiration is derived by the subtraction of non-mitochondrial respiration from the baseline 
respiration. BPTES treated control cells yielded the lowest basal oxygen consumption ratio (OCR), whereas 
itaconate the highest. Compared to control PC12 cells, itaconate yielded a significantly higher basal 
respiration (p = 0.007) whereas Sdhb knockdown resulted in significantly lower basal respiration rate 
compared to mock transfected cells (p = 0.0079). BPTES treatment of cells transfected with siRNA against 
Sdhb or mock transfection did not result in a significant difference in OCR values (Figure 9B). 
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Basal respiration was then evaluated after administration of 2mM glutamine. Only minor changes were 
observed in itaconate (1.4%), atpenin (1.7%), and Sdhb silenced cells (0.5%). BPTES treatment only had a 
significant effect on Sdhb silenced cells when their basal oxygen consumption was compared to the OCR 
after glutamine admission (p = 0.0079). Similarly, a significant difference (p = 0.0079) was observed when 
the OCR of Sdhb silenced cells were compared to mock transfected cells after glutamine admission. BPTES 
treated Sdhb silenced and mock transfected cells’ OCRs after glutamine admission did not differ 
significantly (p = 0.15). 
Maximal respiration is defined as the difference of OCR after 2,4-dinitrophenol (DNP) and after 
antimycin A + rotetone (A+R) admission. Itaconate treatment and siSdhb knockdown significantly increased 
maximal respiration (p = 0.0079). BPTES treatment significantly reduced the maximal OCR of both control 
(p = 0.0079) and siSdhb silenced (p = 0.0079) PC12 cells (Figure 9C). 
Non-mitochondrial respiration is displayed after inhibition both of complex I and complex III with 
A+R. PC12 cells transfected with siRNA against Sdhb had the highest non-mitochondrial respiration which 
did not decrease significantly after BPTES treatment. Both itaconate (p = 0.0159) and siSdhb treatment (p = 
0.0079) significantly increased the non-mitochondrial respiration of PC12 cells (Figure 9D). 
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Figure 9. Oxygen consumption measurements of PC12 cells. (A). Oxygen consumption ratio (OCR %) of PC12 cells. The minimum value of OCR is 0%, maximum 
is 100%. (B) Basal respiration: subtraction of non-mitochondrial respiration from the baseline respiration. (C). Maximal respiration of PC12 cells: difference of OCR 
after 2,4-dinitrophenol (DNP) and after antimycin A + rotetone (A + R) admission. (D) Non-mitochondrial respiration: OCR after inhibition of both complexes I and 
III with A + R. OCR: oxygen consumption ratio; Gln: glutamine; Oligo: oligomycin; DNP: 2,4-dinitrophenol; A + R: antimycin A + rotetone. *: p < 0.05; **: p < 0.01. 
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3. Discussion 
Pheo/PGLs present a genetically heterogenic tumor group, arising from the adrenal medulla or the 
extra-adrenal paraganglia. A total of 40% of these neuro-endocrine tumors are inherited in an autosomal 
dominant manner due to mutations in one of the 17 Pheo/PGL-associated genes [48,49]. Of these genes, 
seven (SDHA, SHDAF2, SDHB, SDHC, SDHD, FH, MDH2) encode enzymes participating in the TCA cycle. 
Mutations of the SDHB gene represent a strong susceptibility for malignancy [50–53]. The precise 
pathomechanism behind the SDHx mutations and especially the malignant potential of SDHB mutations is 
still unknown despite the several observations made through the last decades [54–56]. Unfortunately, there 
is no therapeutic option for malignant cases which warrants further studies to identify novel therapeutic 
targets. Several novel approaches were introduced recently to address the lack of therapeutic options: the 
inhibition of glutathione synthesis was shown to contribute to the DNA damage as a result of the increased 
level of reactive oxygen species in SDHB mutant tumors [57]. Inhibition of complex I made complex II 
impaired tumors more sensitive to DNA damaging chemotherapeutic agents [58] while it has been also 
demonstrated that elevated succinate and fumarate levels suppress the homologous recombination DNA 
pathway, rendering these tumors vulnerable to poly(ADP)-ribose polymerase inhibitors [59]. In addition to 
the lack of therapeutic options, prognostic factors for the prediction of malignant disease are also mandatory 
for establishing a proper strategy for the management of the disease. However, previous attempts show 
that creating a universal prognostic factor for all etiologies of Pheo/PGL is hardly possible [60]. 
The succinate accumulation in SDHx mutant tumors can inhibit the α-ketoglutarate-dependent prolyl 
hydroxylases, which have an important role in the degradation of HIF1α and HIF2α under normoxia [12]. 
Mutations in the SDHB subunit beside the HIF1α stabilization, shift the cellular metabolism towards 
reductive glutamine catabolism [61]. Recently, Lorendeau et al. reported that both loss of complex I and 
complex II activity are necessary to mimic the metabolic phenotype of SDH mutant tumors based on 
reductive glutamine metabolism, sole SDHA or SDHB inhibition failed to do so in their study [62]. Our aim 
was to assess the consequences of SDH impairment in various cell types and to search for novel in vitro 
models, prognostic markers, and therapeutic targets for tumors with reduced or absent SDH activity. 
Knockdown of Sdhb with siRNA in PC12 rat chromaffin cells successfully inhibited SDH activity and 
increased succinate/fumarate ratio by >3 fold compared to mock siRNA transfected cells. Increased 
succinate to fumarate ratio also characteristic for SDH mutant Pheo/PGLs [63]. Based on the metabolite 
measurements, both itaconate and atpenin were more potent SDH inhibitors than Sdhb knockdown. 
Based on the cell viability and oxygen consumption measurements, PC12 cells were not affected 
negatively by SDH impairment. Moreover, these cells showed an overall positive response to SDH 
impairment while HeLa and H295R cells showed decreased viability after itaconate treatment. Atpenin also 
increased HeLa cell line viability, whereas decreased H295R cell line viability. Based on these data we 
assume that the impairment of SDH activity (either by itaconate or atpenin treatments or Sdhb knockdown) 
has a cell type-specific effect on the viability of cells. Significant difference in PC12 cells’ proliferation was 
not observed after SDH impairment in monolayer cell culture. Itaconate treatment of the 3D PC12 cell 
culture model did not decrease the ratio of living cells significantly. Based on these results we conclude that 
PC12 cells can cope with SDH impairment both in the monolayer and the 3D cell culture model. 
Next, we sought to evaluate whether the cell viability effects can be traced back to the differences in 
the metabolite profiles observed after SDH inhibition (beside the differences in the succinate/fumarate 
ratios). In general, inhibition of SDH shifts cellular metabolism to anaerobic glycolysis, and administration 
of itaconate is also associated with lactate accumulation [64]. However, in contrary to HeLa and H295R cell 
lines, the expected increase in lactate concentrations was absent in PC12 cells after itaconate treatment and 
after Sdhb knockout. Sdhb knockdown significantly decreased glutamate concentrations which is in line with 
the data demonstrating that SDHx mutant tumors also accumulate lower levels of glutamate [33], and SDHB 
mutation associated with increased glutamine metabolism [35]. 
In addition, glutamine was shown to be the main source in SDHB-mutated UOK269 cells and this 
metabolite linked HIF-1α stabilization and DNA methylator phenotype [61]. 
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Pursuing the role of glutamine in SDH impaired cells we studied the respiration of SDH impaired PC12 
cells. These cells in the presence of glutamine effectively switch from glycolysis to glutaminolysis which 
increases the basal OCR values. These results are in line with the data published by Zhdanov et al., who 
showed that increase in the OCR values upon mitochondrial uncoupling was only seen when glutamine 
was combined with either glucose or pyruvate. In addition, the cell-specific dependence on glutaminolysis 
was also highlighted [23]. Itaconate but not atpenin had the same effect, it increased the basal respiration of 
PC12 cells whereas it did not have a significant impact on lactate concentration further supporting its 
capability to serve as a model for Sdhb mutant Pheo/PGLs. 
The most significant effect related to oxygen consumption was observed in the non-mitochondrial 
respiration fraction, suggesting that these cells use non-mitochondrial respiration for survival. In 
pheochromocytoma and paragangliomas there is no data about the expression and role of mitochondrial 
uncoupling protein 2 (UCP2) which has been suggested to be a metabolic sensor of cells under nutrient 
shortage. We may hypothesize that in SDH deficient cells a rapid metabolic adaptation occurs which allows 
these cells to survive by either shifting its metabolism to the use of the alternative fuel glutamine or going 
into a reversible, more quiescent state [65]. 
Glutamate has an extensive role in cell metabolism [66] and disruption of the TCA cycle makes the cells 
more dependent on reductive carboxylation of glutamine instead of the oxidative metabolism of the TCA 
cycle [67–69]. GLS-1 is a mitochondrial enzyme that generates glutamate from glutamine, which further 
metabolizes to aspartate and α-ketoglutarate in the mitochondria. GLS-1 has been found to be upregulated 
in some cancers, and in some cases deregulated glutamine metabolism is essential for cancer growth [29–32]. 
Therefore, we sought to assess the expression of GLS-1 in vitro after SDH impairment. PC12 cells 
exhibited significantly increased GLS-1 expression upon Sdhb knockdown and SDH inhibition with 
itaconate too. Interestingly, atpenin treatment decreased the expression of GLS-1 in PC12 cells. HeLa cells 
also exhibited a significant increase in GLS-1 expression upon itaconate treatment. Similar to the PC12 cell 
line, atpenin treatment resulted in significantly decreased GLS-1 expression after 24 h in HeLa cells. 
However, this was reversed after 48 h, when a significant increase in GLS-1 expression was observed. The 
H295R cell line also displayed significantly increased GLS-1 expression after SDH inhibition by either 
itaconate or atpenin. These results indicate that SDH inhibition exhibits cell line and inhibitory method 
specific consequences and the dynamism of metabolic changes varies among cell types, but in PC12 cells 
both Sdhb knockdown and itaconate treatment increased its expression suggesting that these cells might be 
dependent on this enzyme. Contrary, in HeLa and H295R cells, increased GLS-1 expression was not 
necessarily associated with decreased glutamate concentrations. We hypothesize that even though the entry 
for glutamate is enhanced by the increased GLS-1 expression, glutamate is not used effectively after 
itaconate treatment in these cells which further emphasizes the importance of appropriate selection of in 
vitro models. In addition, further studies are warranted to clarify the role of GLS-1 in these cancer cells. 
Based on these observations we evaluated the dependence on GLS-1 function of PC12 cells with 
impaired SDH activity. When SDH inhibition was accompanied by selective GLS-1 inhibition, PC12 cells 
showed significantly decreased proliferation in monolayer cell culture. Increased cell death was observed 
in the 3D PC12 cell culture model, suggesting that chromaffin cells with SDH impairment are dependent 
on the GLS-1 enzyme. It has to be mentioned that currently there is an ongoing clinical trial with the GLS-1 
inhibitor CB-839 for SDH-associated gastrointestinal stromal tumors and non-gastrointestinal stromal 
tumors. However, an earlier study performed in pancreatic cancer showed the limited clinical efficacy of 
CB-839 monotherapy [70] which highlights again that various GLS-1 inhibitors may cause significantly 
different effects on chromaffin cells’ proliferation. 
In order to translate our in vitro data to clinics we examined for the first time the expression of GLS-1 
in various Pheo/PGL tumor tissues with known genetic background by immunohistochemistry. In line with 
in vitro data our immunohistochemistry analysis demonstrated an increased GLS-1 staining in SDHB-low 
expressed tumors compared to tumors with intact SDHB protein. Furthermore, a significant proportion of 
SDHB- and RET-associated malignant tumors also showed an increase in GLS-1 staining compared to 
benign RET-associated and sporadic tumors. It should be also mentioned that in some cases increased GLS-
1 expression was not associated with malignancy. On the other hand, determination of malignancy in Pheo 
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is difficult, because there is no obvious marker for it. Several studies, including a study published by 
Stenman et al., showed that even in RET-associated Pheos, using the “Pheochromocytoma of the Adrenal 
Gland Scaled Score “(PASS) and “Grading System for Adrenal Pheochromocytoma and Paraganglioma” 
(GAPP) algorithms, the malignancy was over-diagnosed [60]. In our study we considered a Pheo malignant 
when the tumor was recurring, or local or distal metastases were detected. In our in vitro experiments, the 
increased GLS-1 expression was not necessarily associated with increased viability, suggesting that for 
increased proliferation, other factors are also needed. The importance of GLS-1 may be the most important 
in SDH-compromised cells, where the concomitant inhibition of SDH and GLS-1 could result in cell 
lethality. The heterogeneous phenotype associated with Sdhb mutations is highlighted in an in vivo model 
of Sdhb mutation developed in Caenorhabditis elegans, where the deleted mutant arrested in development, 
while the point mutant form was viable and it presented only infertility [71]. This further supports 
personalized and case specific treatment of the disease. 
In conclusion, we assume that GLS-1 contributes to SDHB-mutant malignant tumor growth and we 
presume that the evaluation of GLS-1 expression before therapy might yield valuable information for the 
management of the disease. A larger study evaluating malignant and benign Pheo/PGLs with various 
genetic backgrounds would clarify this observation and would decipher to role of GLS-1 in Pheo/PGL cells. 
4. Materials and Methods 
All materials were purchased from Merck-Sigma-Aldrich (Darmstadt, Germany), except where it is 
indicated in the text. 
4.1. Cell Lines 
All cell lines were obtained from American Type Culture Collection (ATCC). Cell cultures were 
incubated at 37 °C in a humidified 5% CO2/95% air atmosphere. 
PC12 cells (rat pheochromocytoma cell line) were grown in 75-cm2 flasks in F-12 (# 21127022 F-12 
Kaigh’s modification, Gibco, Thermo Fisher Scientific, Waltham, MA, USA), containing 15% horse serum 
(Gibco BRL), 5% fetal bovine serum (Gibco BRL), and 1% penicillin-streptomycin (Biosera LM-A4118/100). 
Culture media was replaced three times a week. Cells were removed from flasks for subculture and for 
plating into assay dishes using Trypsin-EDTA solution. 
HeLa cells (human cervix carcinoma cell line) were grown in 75-cm2 flasks in Dulbecco’s modified 
Eagle medium/HamF12 (DMEM/F12) (#11330032, Thermo Fisher Scientific, Waltham, MA, USA) containing 
10% FBS (#10270106, Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin-streptomycin (LM-
A4118/100, Biosera, Nouille, France). Culture media was replaced three times a week. Cells were removed 
from flasks for subculture and for plating into assay dishes using Trypsin-EDTA solution. 
H295R cells (human adrenocortical carcinoma) were grown in 75-cm2 flasks in Dulbecco’s modified 
Eagle medium/HamF12 (DMEM/F12) containing HEPES buffer, L-glutamine, and pyridoxine HCl 
(#11330032, Thermo Fisher Scientific, Waltham, MA, USA). Additional supplements were added to the 
medium, including 0.00625 mg/mL insulin (#I9278, Sigma, St. Louis, MO, USA), 0,00625 mg/mL human 
transferrin (#T5391, Sigma, St. Louis, MO, USA), and 6.25 ng/mL selenous acid (#S9133, Sigma, St. Louis, 
MO, USA) 1.25 mg/mL bovine serum albumine (#A9647, Sigma, St. Louis, MO, USA), 2.5% nu-serum (Zenon 
Bio Kft. Szeged, Hungary), and 1% penicillin-streptomycin (#P0781, Sigma, St. Louis, MO, USA). 
4.2. Sdhb Silencing Using Small Interfering RNA (siRNA) 
PC12 cells were seeded in six-well plates for 24 h before transfection with two Silencer Select small 
interfering RNAs (siRNA A: Sequence (5′–3′: GAUUAAGAAUGAAAUCHAUtt, siRNA ID: #s151576; 
siRNA B: Sequence (5′–3′: GCAAAGUCUCGAAAAUAUAtt, siRNA ID: #s220846) (Ambion, Thermo Fisher 
Scientific, Waltham, MA, USA) targeting SDHB using RNAiMAX Reagent (Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. For negative control, cells 
cultured under identical conditions were transfected with non-targeting Silencer Select siRNA (Ambion by 
Life Technologies). Specific effect of siRNA against Sdhb was verified by Western blot analysis. 
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4.3. Protein Extraction and Western Blot 
Total protein was extracted with M-Per reagent (#78503, Thermo Fisher Scientific, Waltham, MA, USA), 
according to the manufacturer’s instructions. Protein concentrations were determined by BCA Assay 
(Sigma, St. Louis, MO, USA). Total protein was separated by 10–15% SDS polyacrylamide gel 
electrophoresis, transferred to a PVDF membrane, and incubated overnight with primary antibody against 
SDHB (5 µg/mL; anti-SDHB, ab14714, Abcam, Cambridge, United Kingdom). Spectra Multicolor Broad 
Range Protein Ladder (#26634, Thermo Fisher Scientific, Waltham, MA, USA) was used as a protein ladder. 
For loading control membranes were stripped and re-probed using mouse anti-β-actin (1:25,000, Cell 
Signaling Technology, ZA, Leiden, The Netherlands). Anti-mouse HRP-conjugated IgG was used as 
secondary antibody (1:2,000, #P044701, Agilent, Santa Clara, CA, USA). Band intensities were quantified 
using Image J software (National Institutes of Health, Bethesda, MD, USA). 
4.4. Biochemical Inhibition of SDH Enzyme 
Itaconic acid was purchased from Sigma (#I29204, Sigma-Aldrich (Sigma, St. Louis, MO, USA). The 500 
mM stock solutions were prepared with nuclease free water; pH 7.2 was adjusted with NaOH. 
Cells were seeded onto six-well plates. After 24 h incubation, the used medium was replaced by fresh 
medium, after washing with PBS. Then, 25 mM itaconic acid was added in the wells. Nuclease free water 
was used as control. 
Atpenin A5 (atpenin) used for our study was a generous gift from Christos Chinopoulos. Atpenin was 
purchased from Enzo Life Sciences (#ALX-380-313-MC25, Enzo Life Sciences, Inc., Farmingdale, NY, USA). 
First, 2mM stock solution was prepared with absolute ethanol. Cells were seeded onto six-well plates. After 
24 h incubation, the used medium was replaced by fresh medium, after washing with PBS. Then, 1 µM 
itaconic acid was added in the wells. Absolute ethanol in the same treatment volume was used as control. 
4.5. Inhibition of GLS-1 Activity 
Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl) ethyl sulfide (BPTES) was purchased from Sigma 
(#SML0601, Sigma-Aldrich (Sigma, St. Louis, MO, USA). The 2mM stock solutions were prepared with 
DMSO. Then, 10 µM BPTES was added to the cells. DMSO was used as control. 
4.6. Cell Viability and Proliferation Assays 
AlamarBlue test was used (Thermo Fisher Scientific, Waltham, MA, USA) to determine the viability 
effects of itaconic acid and atpenin treatment after 24, 48, and 72 h in PC12, HeLa, and H295R cells and in 
PC12 cells after transfection of siRNA against Sdhb or mock siRNA and after co-treatment with BPTES. The 
assay was performed in 96-well plates. All treatments at each time point and siRNA transfections were 
performed in six replicates, outliers were excluded before the statistical analysis. For studying the viability 
changes with AlamarBlue assay, PC12 cells were plated in 100 µL cell culture media at a density of 5000 
cells/well for 24h treatment, 2500 cells/well for 48 h treatment, and 1700 cells/well for 72 h treatment. HeLa 
cells were plated in 100 µL cell culture media at a density of 3000 cells/well for 24 h treatment, 1500 cells/well 
for 48 h treatment, and 1000 cells/well for 72 h treatment. H295R cells were plated onto 96-well culture 
plates in 100 uL cell culture media at a density of 10000 cells/well for 24 h treatment; 5000 cells/well for 48 
h treatment; 3500 cells/well for 72 h treatment. After 24 h, cell media was replaced by fresh media, and 
itaconate, atpenin, or siRNA against Sdhb treatment was performed. After the given incubation time, 10 µL 
AlamarBlue, was added to each well. After 1 h and 15 min incubation at 37 °C, fluorescence was measured 
in the 560-590 nm range using Varioskan Flash plate reader (Thermo Fisher Scientific). Percentage of the 
cell proliferation was given relative to control samples. 
Sulforhodamine B (SRB) assay was used for evaluation of proliferation of PC12 cells. The cells were 
seeded onto 96-well plates at a density of 2500 cells/well. Each measurement was performed six replicates. 
After incubation with the indicated drug concentrations for 24/48/72 h, cells were fixed by cold 10% 
trichloroacetic acid for 60 min in 4 °C, washed with water, and dried. After drying, cells were incubated 
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with 0.4% sulforhodamine B (Sigma-Aldrich) for 15 min in RT. After washing with 1% acetic acid, the 
protein-bound dye was dissolved in 10 mM Tris. The absorbance at 570 nm was measured in LabSystems 
Multiskan RC/MS/EX Microplate Reader (Artisan Scientific, Champaign, IL, USA). 
4.7. 3D Culturing of PC12 cells 
The PC12 rat cell line was seeded with a density of 500,000 cells per six-well (2 mL/well) at 37 °C and 
5% CO2. For spheroid induction serum-free defined media (Lichner et al. 2015) containing Ham’s F-12K 
(Kaighn’s) Medium (Gibco; Thermo Fisher Scientific) with 2% B27 Supplement, 50 ng/mL EGF and 50 
ng/mL FGF was used. After spheroid formation (96 h) cells were treated with 500 nM itaconate and 10 µM 
itaconate-BPTES solution for 24, 48, and 72 h. 
In 3D structure biochemical assays for proliferation and viability are not reliable due to uncertain 
diffusion of the reagent into the inner/central part of the spheroids. Therefore, viable and dead cells were 
investigated by trypan blue staining method. Spheres were dissociated with trypsine then they were stained 
with 0.4% (w/v) trypan blue solution (Life Technologies, California, CA, USA). Cell growth and the number 
of live and dead cells were assessed under Burker chamber. 
4.8. Measurement of the Intracellular Concentration of Metabolites Using Liquid Chromatography Mass 
Spectrometry (LC-MSMS) 
Cells were grown in six-well plates. All experiments (treatment with itaconic acid and siRNA 
transfection) were made in three replicates except for 24 h itaconic acid treatment of PC12 cells, where nine 
biological replicates were carried out. 
Intracellular metabolites (lactate, pyruvate, citrate, α-ketoglutarate, succinate, fumarate, malate, 
glutamate, aspartate) were extracted by a modified method based on Szoboszlai et al. [72]. In brief, the cells 
were quenched in liquid nitrogen and extracted by mixture of MeOH–chloroform–H2O (9:1:1) and vortexed 
at 4 °C. After centrifugation (15,000× g, 10 min, 4 °C) the clear supernatants were kept at −80 °C until liquid 
chromatography-mass spectrometry (LC-MS) measurements. The concentrations of lactate, citrate, 
succinate, fumarate, malate, glutamate, and aspartate were assessed by using calibration curves obtained 
with the dilution of analytical grade standards in the range of 0.5–50 µM. LC-MS assays were used by 
Perkin-Elmer Flexar FX10 ultra-performance liquid chromatograph coupled with a Sciex 5500 QTRAP mass 
spectrometer. Chromatographic separation was carried out on a Phenomenex Luna Omega C18 column 
(100 × 2.1 mm, 1.6 µm) (GenLab Ltd., Budapest, Hungary). The mobile phase consisted of water and 
methanol containing 0.1% (v/v) formic acid. The MS was operating in negative electrospray ionization mode. 
For the measurements the following settings were adjusted—source temperature: 300 °C ionization voltage: 
-4000 V, entrance potential: −10 V, curtain gas: 35 psi, gas1: 35 psi, gas2: 35 psi, CAD gas: medium. Multiple 
reaction monitoring (MRM) mode was applied to perform quantitative analyses. All samples were 
measured in triplicate. Concentrations of metabolites were normalized to DNA concentration isolated from 
cells plated, incubated, and treated in the same manner as cells used for metabolite analysis. The cells were 
trypsinized and DNA was extracted using the semiautomatic DNA isolation protocol with QIAcube 
instrument (Qiagen, Hilden, Germany). The concentration of the extracted DNA samples was measured 
with NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). 
4.9. Expression of SDHB and Glutaminase Type 1 (GLS-1) in Hereditary Pheochromocytoma/Paraganglioma 
Tissues Using Immunohistochemistry 
Representative tissue blocks (n = 35) from 29 patients with Pheo/PGL were evaluated by two expert 
pathologists. Eleven patients had hereditary Pheo/PGLs (five carried SDHB and six patients carried the RET 
mutation (Table 1). Informed consent was obtained from all subjects and the experiments conformed to the 
principles set out in the WMA Declaration of Helsinki. Our study was approved by the Scientific and 
Research Committee of the Medical Research Council of Ministry of Health, Hungary (ETT-TUKEB 
4457/2012/EKU). 
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Malignancy was diagnosed when a tumor was recurring, or local or distal metastases were detected. 
Of 35 tissue samples 13 were classified as malignant (six related to SDHB while four to RET mutations, no 
pathogenic mutations were detected in three malignant cases). Immunostaining of SDHB and GLS-1 was 
performed as previously described [73]. In brief, 4 µm-thick sections of formalin-fixed paraffin-embedded 
were used. After deparaffinization and blocking the endogenous peroxidases, antigen retrieval was 
performed for 30 min (10 mM citrate pH 6.0) using a pressure cooker. Slides were incubated with anti-
glutaminase (ab156876, Abcam) and anti-SDHB (ab14714, Abcam) primary antibodies. 
Immunohistochemical reactions were visualized using Novolink Polymer (Leica Biosystems, Wetzlar, 
Germany) detection system and 3,3′-Diaminobenzidine (DAB, Dako) chromogen, followed by hematoxylin 
counterstain. Immunoreactivity was assessed in tumor cells (and normal adrenal medulla cells as control) 
using H-scores [74], which range from 0 to 300 and were calculated by multiplying the intensity of staining 
(0—no staining, 1+—weak staining, 2+—moderate staining, or 3+—strong staining) and the percentage of 
immunopositive cells (0–100). For example, 40% of tumor cells staining positive with moderate intensity 
(2+) and 10% of the tumor cells staining with strong intensity (3+) results in an H-score of 110. Based on H-
score, expression of SDHB and GLS-1 was classified as ‘low’ (H-score < 100) and ‘high’ (H-score ≥ 100). 
4.10. GLS-1 Gene Expression Measurements 
Experiments were performed in six-well plates in duplicates for RNA isolation. Total RNA was 
harvested using RNeasy Mini Kit (50) (#74104, Qiagen, Hilden, Germany), according to the manufacturer’s 
instructions. RNA concentrations were determined with NanoDrop 1000 Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA, USA). For the quantitative real-time PCR (qRT-PCR) experiments, 1 µg of 
total RNA was reverse transcribed using High-Capacity RNA-to cDNA Kit (#4387406, Thermo Fisher 
Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. For gene expression 
measurements, predesigned TaqMan Gene Expression assays were used (rat GLS: Rn00561285_m1, human 
GLS-1: Rn00667869_m1, rat actin: Rn00667869_m1, human actin: Hs99999903_m1; all from Applied 
Biosystems by Life Technologies). cDNA was diluted 100×. All measurements were performed in triplicate. 
DeltaCT (dCT) values were calculated and deltadeltaCT (ddCT) values were normalized to the controls in 
the experiments. Fold change values were calculated from 2−ddCT. 
4.11. Cellular Respiration 
Seahorse XF96 Analyzer (Agilent Technologies, Santa Clara, CA, USA) was used to assess real-time 
oxygen consumption rate (OCR), reflecting mitochondrial oxidation and extracellular acidification rate 
(ECAR), based on previous descriptions [40,75,76]. PC12 cells were plated in 100 µL complete medium at 
30,000 cells/well density onto 96-well Seahorse plates (Agilent Technologies, Santa Clara, CA, USA) 24 h 
prior to the assays. Itaconate (25 mM) or atpenin (1 µM) treatment was carried out 24 or 48 h before the 
assays, whereas transfection with siRNA against Sdhb or mock vector 48 h before the assays. BPTES 
treatment was carried out 24 h prior to the assay. On the day of the assay complete medium was removed 
and was replaced by a medium containing (in mM): 120 NaCl, 3.5 KCl, 1.3 CaCl2, 1.0 MgCl2, 20 HEPES, 
10 glucose at pH 7.4. The basal OCR and ECAR values were calculated after 1.5 h incubation at this 
condition. 
During the measurements freshly prepared glutamine (4 mM) and/or metabolic inhibitors/modulators 
(oligomycin 2 µM, 2,4-dinitrophenol- DNP 200 µM and antimycin A + rotetone 1-1µM) were injected into 
each well to reach the desired final working concentration. 
4.12. Oxygen Consumption of PC12 Cells 
Oxygen consumption was performed polarographically using an Oxygraph-2k (Oroboros Instruments, 
Innsbruck, Austria). Two T75 flasks of approx. 80% confluent PC12 cells were suspended in 2 mL incubation 
medium, containing, in mM: mannitol 225, sucrose 125, Hepes 5, EGTA 0.1, KH2PO4 10, MgCl2 1, glutamate 
5, malate 5, succinate 5, 0.5 mg/mL bovine serum albumin (fatty acid-free), pH  =  7.25 (KOH). Experiments 
were performed at 37 °C in 8–12 parallel wells. Oxygen concentration and oxygen flux (pmol·s−1·mg−1; 
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negative time derivative of oxygen concentration, divided by mitochondrial mass per volume) were 
recorded using DatLab software (Oroboros Instruments). 
4.13. SDH Activity Measurement 
SDH activity was assessed as described previously [77]. Briefly, the oxidation of succinate by 
decylubiquinone was coupled to the reduction of dichlorophenolindophenol (DCPIP), and the rate was 
followed spectrophotometrically at 600 nm at 30 °C. 
4.14. Statistical Analysis 
All data are expressed as mean ±SD except where it is indicated otherwise. Statistical analysis was 
performed using GraphPad Prism 6 software (GraphPad Software Inc., La Jolla California, CA, USA). 
Gaussian distribution of data was evaluated with Shapiro–Wilks test. In the case of normally distributed 
data the differences were analyzed by Student’s t-test, otherwise by rank sum test. Correlation in case of 
normally distributed data was calculated with a Pearson test, otherwise a Spearmen test was used. p values 
of <0.05 were considered to be statistically significant. 
5. Conclusions 
In summary, we demonstrated for the first time that SDH inhibition either with itaconate, atpenin, or 
SDHB knockdown had a positive effect on cell viability of chromaffin cells but not on other cell lines which 
may be related to the glutamine/glutamate metabolism. The aim of our study was to establish a cost-efficient 
model for the research of novel prognostic factors and therapeutic agents before conducting further, more 
complex and more expensive studies, however we acknowledge the limitations of our research. Lack of 
availability of SDHB-mutant animal model developing Pheos [20] warrants other in vitro and in vivo 
models for deciphering the mechanism contributing to the malignant behavior of these rare tumors. SDHB 
expression in some SDHB-mutant Pheo/PGL tissues suggests that tumor heterogeneity occurs even in 
SDHB-associated tumors. In addition, by measuring the succinate to fumarate ration in various Pheo tumors 
it was shown that the remaining SDH activity was highly variable [63]. All together these data suggest that 
some SDH activity is still maintained in these tumors, therefore knockdown of SDHB by siRNA provides a 
feasible model for the disease. As itaconate treatment of PC12 cells successfully mimicked the phenotype 
observed in the Sdhb silenced cells, it can be a useful, easily accessible in vitro model for these tumors. The 
importance of glutamine/glutamate metabolism of cells lacking SDH was confirmed by our in vitro 
experiments demonstrating the upregulation of GLS-1 after SDH inhibition (either by chemical agents or 
Sdhb knockdown) and by the decreased proliferation upon GLS-1 inhibition. The importance of GLS-1 was 
also reassured by evaluation of expression of GLS-1 in malignant PGL tissues compared to benign tumors. 
Our data suggests that GLS-1 inhibition in SDH deficient chromaffin cells tumors may represent novel, 
tumor specific alternatives of therapy in malignant Pheo/PGL where the current treatment options are 
limited. Moreover, as reliable markers of malignant Pheos are lacking, GLS-1 staining seems to be worthy 
of further investigations as a potential marker of Pheo/PGL malignancy. 
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